

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q85706

Osami HABUCHI, et al.

Appln. No.: National Stage Entry of PCT/JP03/08785

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: January 10, 2005

Examiner: Unknown

For: SULFOTRANSFERASE INHIBITOR

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/520659

DT12 Rec'd PCT/PTO 10 JAN 2005

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: National Stage Entry of PCT/JP03/08785
Attorney Docket No.: Q85706

filings a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Each of the referenced documents is cited in the corresponding International Search Report for PCT/JP03/08785 dated October 28, 2003, copy enclosed.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,


Mark Boland
Registration No. 32,197

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: January 10, 2005

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	Q85706
-------	---	----	---	------------------------	--------

Complete if known
10/520659

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	97/00879	A1	01-09-1997	ISM. Institute for Socio-Medical Research	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Osami HABUCHI et al, Sulfation of p-Nitrophenyl-N-acetyl-β-D-galactosaminide with a Microsomal Fraction from Cultured Chondrocytes, The Journal of Biological Chemistry, 1985, Vol. 260, No. 24, pages 13102 to 13108	
		Paul E. FRASER et al, Amyloid-β Interactions with Chondroitin Sulfate-derived Monosaccharides and Disaccharides, The Journal of Biological Chemistry, 2001, Vol. 276, No. 9, pages 6412 to 6419	
		Kiyoshi IKEDA et al, Synthesis of N-Acetylglucosaminyl- and N-Acetylgalactosaminylceramides as Cerebroside Analogs and Their Anti-human Immunodeficiency Virus Type 1 Activities, Chem. Pharm. Bull., 1997, Vol. 45, No. 2, pages 402 to 405	
		Barbara FAROUX-CORLAY et al, Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity, Carbohydrate Research, 2000, Vol. 327, pages 223 to 260	
		Tina HORROBIN et al, Esterase-catalysed regioslective 6-deacylation of hexopyranose per-acetates, acid-catalysed rearrangement to the 4-deprotected products and conversions of these into hexose 4-and 6-sulfates, J. Chem. Soc., Perkin Trans. 1, 1998, pages 1069 to 1080	
		Kazuyuki SUGAHARA et al., Regulation of Serum Glycosaminoglycan Sulfotransferase Activities: Inhibition by Sulfated Glycosaminoglycans and Activation by Polyamines and Basic Peptides Including a Polylysine-Containing Segment of the c-Ki-ras 2 Protein, J. Biochem. 1989, Vol. 106, pages 910 to 919	
		International Search Report dated October 28, 2003	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.